Modernland Realty Ltd
MDLN
$36.66
-12.79%
Medline Inc. is the largest provider of medical-surgical products and supply chain solutions in the United States, offering a vast catalog of roughly 190,000 Medline-branded products and 150,000 third-party items across more than 250 product families. The company's dominant market position is anchored by its prime vendor relationships with major US health systems, supported by over 30 manufacturing facilities and a fleet of 2,000 delivery trucks. As a newly public company (listed December 2025), Medline's investor narrative is centered on its ability to sustain growth and margin expansion while navigating recent operational disruptions, including a distribution center fire and FDA safety concerns, which have introduced near-term uncertainty and weighed on the stock's post-IPO performance.…
MDLN
Modernland Realty Ltd
$36.66
Related headlines
Investment Opinion: Should I buy MDLN Today?
Based on the analysis, Medline is rated a Buy with a thesis that its dominant market position and expected earnings recovery will drive the stock toward the analyst average target of $50.65, representing 28.9% upside. The consensus recommendation is 'Buy' with a mean score of 1.54, and the forward PE of 23.59x is reasonable for a company with 10.66% revenue growth. Supporting evidence includes strong revenue growth, a healthy current ratio, and a low PS ratio of 1.20, which is attractive relative to peers. However, the stock faces risks from operational disruptions and margin pressure, which could delay the recovery. This Buy rating would be downgraded to Hold if the stock fails to hold above $35 or if revenue growth decelerates below 8%, and upgraded to Strong Buy if the stock breaks above $45 on strong earnings. Overall, Medline appears fairly valued to slightly undervalued given its growth prospects and analyst targets.
Sign up to view all
MDLN 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the company's fundamentals are sound, with strong revenue growth and a reasonable valuation, the near-term operational risks and negative price momentum create uncertainty. The stock's performance will likely hinge on the resolution of the distribution center fire and FDA issues. If these are resolved quickly, the stock could rally to the analyst target; if not, it may test the 52-week low. The AI stance would upgrade to bullish if the stock breaks above $45 on strong earnings, and downgrade to bearish if it falls below $35.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Modernland Realty Ltd's 12-month outlook, with a consensus price target around $50.65 and implied upside of +38.1% versus the current price.
Average Target
$50.65
0 analysts
Implied Upside
+38.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $62
Analyst target range
Medline is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.54 (where 1 is Strong Buy and 5 is Sell), indicating a strongly bullish stance. The average target price is $50.65, implying a substantial 28.9% upside from the current price of $39.28. The distribution of ratings is not explicitly provided, but the low mean score suggests a majority of Buy or Outperform ratings, with only a few Neutral or Sell. Recent institutional actions have been predominantly reaffirmations of Buy/Overweight ratings, with no downgrades, reinforcing the positive sentiment.
Bulls vs Bears: MDLN Investment Factors
Medline presents a mixed picture: strong revenue growth and a bullish analyst consensus are offset by operational disruptions, margin pressure, and a weak stock price trend. The bull case relies on the company's market leadership and expected earnings recovery, while the bear case focuses on near-term headwinds and high leverage. Currently, the bearish evidence is slightly stronger given the stock's downtrend and recent operational issues, but the potential for a rebound is significant if the company resolves its challenges. The key tension is whether the operational disruptions are temporary or signal deeper structural problems, which will determine the stock's trajectory.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 10.66% YoY to $7.352B, up from $6.644B in Q1 2025, demonstrating consistent demand for medical supplies. This growth is supported by the company's dominant market position and prime vendor relationships with major US health systems.
- Analyst Consensus is Strongly Bullish: With 26 analysts, the consensus is 'Buy' with a mean score of 1.54 (1=Strong Buy, 5=Sell). The average target price of $50.65 implies a 28.9% upside from the current price of $39.28, indicating significant expected appreciation.
- Forward PE Suggests Earnings Growth: The forward PE of 23.59x is lower than the trailing PE of 29.37x, implying the market expects earnings to grow by approximately 24.5%. This optimism is likely driven by operational efficiencies and recovery from recent disruptions.
- Healthy Current Ratio: The current ratio of 4.29 indicates strong short-term liquidity, with ample current assets to cover current liabilities. This provides a buffer against operational disruptions and supports ongoing investment in growth.
Bearish
- Stock in Downtrend Since IPO: The stock is down 22.8% from its 52-week high of $50.876 and trading near the lower end of its range, reflecting persistent selling pressure. The 6-month change of -11.13% and relative strength of -19.09% vs SPY underscore weak momentum.
- Operational Disruptions: A major distribution center fire and an FDA warning letter on homecare beds create near-term operational and financial challenges. These events could disrupt supply chains, increase costs, and damage customer trust, impacting revenue and margins.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 1.17 indicates significant leverage, which increases financial risk. High interest expenses (e.g., $165M in Q1 2026) could pressure net income if rates rise or cash flows weaken.
- Declining Gross Margin: Gross margin fell to 22.65% in Q1 2026 from 24.82% in Q1 2025, a decline of over 200 basis points. This suggests rising input costs or pricing pressure, which could erode profitability if not reversed.
MDLN Technical Analysis
Medline's stock has been in a clear downtrend since its IPO, with the current price of $39.28 representing a 22.8% decline from its 52-week high of $50.876, while sitting 19.7% above its 52-week low of $32.815. The stock is trading at 38.5% of its 52-week range (calculated as (39.28-32.815)/(50.876-32.815)), indicating it is closer to the lows than the highs, reflecting persistent selling pressure and a lack of buyer conviction. The 1-year price change is not directly available, but the 6-month change of -11.13% and YTD change of -3.30% underscore a weak longer-term trend, with the stock failing to establish a sustained uptrend since its listing.
Beta
—
—
Max Drawdown
-33.6%
Largest decline past year
52-Week Range
$33-$51
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MDLN Return | S&P 500 |
|---|---|---|
| 1m | -14.2% | +2.5% |
| 3m | -12.4% | +5.2% |
| 6m | -22.5% | +11.5% |
| 1y | — | +22.6% |
| ytd | -9.7% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLN Fundamental Analysis
Medline's revenue trajectory shows solid growth, with Q1 2026 revenue of $7.352 billion, up 10.66% year-over-year from $6.644 billion in Q1 2025. This growth is consistent with the prior year's trend, as quarterly revenues have risen from $6.185 billion in Q2 2024 to $7.787 billion in Q4 2025, indicating a steady expansion. However, the growth rate has decelerated from the 11.3% YoY growth seen in Q2 2025 (calculated from $6.886B vs $6.185B) to the current 10.66%, suggesting a slight cooling but still healthy demand for medical supplies. The company's scale and prime vendor relationships likely drive this growth, though segment data is not available to pinpoint specific drivers.
Quarterly Revenue
$7.4B
2026-03
Revenue YoY Growth
+10.7%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLN Overvalued?
Given Medline's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 29.37x, while the forward PE is 23.59x, implying the market expects earnings growth of about 24.5% (calculated as (29.37/23.59)-1). This forward discount suggests analysts anticipate improved profitability, likely driven by operational efficiencies and recovery from recent disruptions. The PEG ratio is negative at -4.96, which is not meaningful due to expected earnings declines in the near term, but the gap between trailing and forward PE indicates optimism about future earnings power.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Medline carries a debt-to-equity ratio of 1.17, indicating substantial leverage that could strain cash flows, especially with interest expenses of $165M in Q1 2026. The company's net margin is thin at 4.08%, leaving little room for error; a modest decline in revenue or increase in costs could turn profits into losses. Additionally, the negative PEG ratio suggests expected earnings declines, which could pressure the stock if realized. However, the current ratio of 4.29 provides a strong liquidity buffer, mitigating near-term solvency risks.
FAQ
The key risks are: 1) Operational disruptions from the distribution center fire and FDA warning letter, which could hurt revenue and margins. 2) High leverage with a debt-to-equity ratio of 1.17, increasing financial risk. 3) Margin compression, as gross margin fell to 22.65% in Q1 2026 from 24.82% a year ago. 4) Market risk, as the stock has underperformed the S&P 500 by 19.09% over the past 6 months. The most severe risk is a prolonged operational crisis that leads to customer losses and a decline to the 52-week low of $32.815, representing a potential 16.5% loss from the current price.
The 12-month forecast is mixed: the bull case (30% probability) targets $50-$62, the base case (45% probability) targets $45-$55, and the bear case (25% probability) targets $33-$40. The most likely scenario is the base case, with the stock reaching the average analyst target of $50.65, assuming the company resolves its operational issues and maintains revenue growth. The key assumption is that the distribution center fire and FDA concerns are contained without lasting damage. If these issues persist, the stock could fall to the bear case target.
MDLN is fairly valued to slightly undervalued based on its forward PE of 23.59x, which is reasonable for a company with 10.66% revenue growth. The PS ratio of 1.20 is low, suggesting the market is not paying a premium for sales. However, the trailing PE of 29.37x is higher, reflecting past earnings that were impacted by operational issues. The market expects earnings growth of 24.5% as indicated by the forward PE discount. Overall, the valuation implies that the market is cautiously optimistic about the company's future, but not overly so.
MDLN is a good buy for investors with a medium-to-long-term horizon who are comfortable with near-term volatility. The stock offers a 28.9% upside to the average analyst target of $50.65, and the consensus is 'Buy'. However, the stock is in a downtrend and faces operational risks, so it is not suitable for short-term traders. A good entry point would be near the current price or lower, with a stop-loss below $35. For long-term investors, the company's market leadership and growth prospects make it an attractive addition to a diversified portfolio.
MDLN is more suitable for long-term investment due to its growth potential and market position, but it is not ideal for short-term trading given its high volatility and negative momentum. The stock has a beta that is not provided, but its price swings are significant, as seen in the 22.8% decline from its high. The company's earnings visibility is moderate, with revenue growth expected to continue but subject to operational risks. For long-term investors, a minimum holding period of 12-18 months is recommended to allow for the resolution of current issues and realization of growth. Short-term traders may find opportunities in the volatility, but the risk is high.